Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinoma.
Genetic single nucleotide polymorphisms (SNP) play a critical role in the development of esophageal squamous cell carcinoma (ESCC). The aim of this study is to investigate the associations between insulin-like growth factor binding protein-3 (IGFBP-3) gene polymorphisms and ESCC patients risk and survival after definitive chemoradiotherapy (CRT). We undertook a case-control study to analyze two IGFBP-3 polymorphisms (rs2854744 A>C and rs2854746 G>C) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 110 ESCC patients treated with CRT and 128 control participants, and performed IGFBP-3 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in rs2854746 G>C. However, rs2854744 A>C genotype was at increased risk of ESCCs (P=0.032; odds ratio (OR)=1.201, CI 95%:1.014-1.423). Moreover, rs2854744 A>C genotype ESCCs were more significantly common in patients with tumor size of >6cm than A allele ESCC and in cases of lower T stage. Furthermore, ESCC patients with rs2854744CC genotype have the poorer CRT response and shorter survival time than GG+GC genotype ESCC. In conclusion, polymorphism in IGFBP-3 rs2854744 A>C might be a potential predictor of ESCC risk and patient survival. Nevertheless, further investigation with a larger sample size is needed to support our results.